Nā hualoaʻa hoʻohiki i ka hoʻopaʻa ʻana i ka maʻi maʻi pancreatic hou

Ua hoʻolaha ʻo SIWA Therapeutics, Inc., kahi hui biopharmaceutical ma Chicago i kēia lā, ʻo ka SIWA ponoʻī kanaka monoclonal antibody, SIWA318H, he mea pono i loko o kahi kumu hoʻohālike xenograft ʻiole hoʻomaʻamaʻa kūlohelohe no ka maʻi maʻi pancreatic. Ua mālama ʻia ke aʻo ʻana e ka Translational Genomics research Institute (“TGEN”), e like me ka ʻaelike noiʻi kākoʻo ʻia e SIWA.

ʻO nā hopena o ke aʻo ʻana i ka maʻi maʻi pancreatic i nā ʻiole kanaka i mālama ʻia me SIWA318H:

• Ua hōʻike nā pūʻulu lapaʻau kiʻekiʻe SIWA318H a me nā pūʻulu lapaʻau haʻahaʻa i ka hana anti-tumor koʻikoʻi i loko o ka PSN1 kanaka pancreatic cancer mouse xenograft tumor model ma o ka hoʻohaʻahaʻa nui ʻana i ka ulu ʻana o ka tumor (P-Value <0.0001);

• Loaʻa ka nui o nā hihia kalahala piha i nā hui i mālama ʻia i hoʻohālikelike ʻia me ka pūʻulu hoʻokele isotype-treated.

ʻO 37.5% (6 mai 16 mau ʻiole) i mālama ʻia me ka SIWA318H kiʻekiʻe kiʻekiʻe i loaʻa ka pane kala kala piha; (P-waiwai = 0.0325)

ʻO 43.8% (7 mai 16 mau ʻiole) i mālama ʻia me ka SIWA318H haʻahaʻa haʻahaʻa loaʻa ka pane kala kala piha; (P-waiwai = 0.0143)

• ʻO ka SIWA318H i mālama ʻia he ʻiole maikaʻi ke ola holoʻokoʻa ma mua o 45 mau lā i hoʻohālikelike ʻia me 26 mau lā o ke ola holoʻokoʻa holoʻokoʻa no nā holoholona hoʻomalu, e hōʻike ikaika ana i ka pono lapaʻau no ka mālama ʻana i ka maʻi maʻi pancreatic i loko o ke kanaka.

• ʻAʻohe ʻokoʻa koʻikoʻi o ka hoʻololi ʻana i ke kaumaha o ke kino ma waena o nā pūʻulu hoʻomalu a me nā hui lapaʻau, e hōʻike ana i ka SIWA318H i nā kau i hoʻohana ʻia ua ʻae maikaʻi ʻia.

"Ua hauʻoli nui mākou i ka ʻike ʻana o SIWA318H i kēia noiʻi a me ke ʻano o kēia i ka hakakā ʻana i ka maʻi kanesa," wahi a Lewis Gruber, Luna Nui a Luna Nui ʻepekema o SIWA. "Ua hoʻomohala ʻo SIWA i ʻelua ʻaoʻao i ka maʻi kanesa ma o ka hoʻohana ʻana i ka SIWA318H e hoʻomaʻemaʻe i nā pūnaewele maʻi maʻi a me nā cell senescent i loko o ka micro-environment tumor e kākoʻo ana iā lākou. Ke manaʻoʻiʻo nei mākou i kēia hiki ke hoʻopaʻa ʻia i nā cell cancer a me nā cell senescent e hana i ka SIWA318H he immunotherapy piha no nā maʻi maʻi āpau a me ka hoʻōki ʻana i ka piʻi ʻana o ka maʻi maʻi, metastasis, a me ka hoʻi hou ʻana.

Ua hōʻike ʻo SIWA ma muli o kāna mau hopena me ka maʻi maʻi pancreatic a me ka metastasis, a ma muli o nā hopena e hōʻike ana i ka hōʻemi nui ʻana o ka metastases o ka māmā ma kahi ʻano ʻiole 4T1 o ka maʻi maʻi umauma triple negative me ka homolog waha o SIWA318H (P-value ≤ 0.001), manaʻo ia. e waiho i kāna IND mua me ka FDA ma 2023 no ka maʻi maʻi pancreatic. Manaʻo ia e noi i ka FDA e hāʻawi i kahi koho FastTrack.